Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

How Are Acromegaly Medications Administered?

At a Glance

Acromegaly medications are administered through long-acting monthly injections at a clinic, daily self-injections at home, or oral pills. The method depends on your specific prescription, such as octreotide, pegvisomant, or cabergoline, and whether your hormone levels are well-controlled.

The administration route of acromegaly medications is a major factor in daily life, and the options range from monthly clinic visits to daily self-injections or pills. The delivery method depends on the specific medication your endocrinologist prescribes, such as a somatostatin receptor ligand (SRL), a growth hormone receptor antagonist, or a dopamine agonist.

Quick Reference: Medication Administration

Medication Type Route Frequency Given By Storage
Octreotide LAR / Pasireotide LAR Injectable SRL Deep intramuscular (IM) Usually every 4 weeks Healthcare Professional Refrigerated
Lanreotide Injectable SRL Deep subcutaneous Usually every 4 weeks HCP or Trained Patient/Partner Refrigerated
Pegvisomant GH Receptor Antagonist Subcutaneous Daily Patient or Caregiver Refrigerated
Oral Octreotide Oral SRL Pill (Capsule) Twice daily Patient Refrigerated (until open)
Cabergoline Dopamine Agonist Pill (Tablet) 1–2 times weekly Patient Room Temp

Long-Acting Injections (Every 3 to 8 Weeks)

First-line medical therapies for acromegaly often involve first-generation Somatostatin Receptor Ligands (SRLs) like octreotide and lanreotide. These medications, along with second-generation options like pasireotide, are formulated to be long-acting and are typically given once every 4 weeks [1][2]. For patients whose hormone levels stabilize exceptionally well, doctors can sometimes extend the injection interval to every 6 to 8 weeks.

  • Octreotide LAR and Pasireotide LAR: These medications require a deep intramuscular (IM) injection, usually into the gluteal muscle (the buttocks) [3][2]. Because the medication requires specific mixing and the needle is thick enough to reach deep into the muscle, these must be administered by a healthcare professional in a clinical setting [3]. The muscle will likely be sore for a few days, so avoiding sitting heavily on that side immediately after can help minimize discomfort.
  • Lanreotide (Somatuline Depot): Unlike the intramuscular medications, lanreotide is administered as a deep subcutaneous (under the skin) injection [1][2]. While it is often given by a nurse or doctor, some patients or their trained partners can safely self-administer it at home [2]. Research shows patients generally report fewer injection-site problems and less anxiety with subcutaneous lanreotide compared to intramuscular octreotide [2][4]. Storage note: This medication must be kept in the refrigerator.

Daily Injections

For patients whose condition is not fully controlled by SRLs, or who experience side effects, doctors may prescribe a growth hormone receptor antagonist called Pegvisomant [5].

  • How it is given: Pegvisomant requires a daily subcutaneous injection [5].
  • Who administers it: Because it must be taken daily, patients or their caregivers self-administer the medication at home [6]. Comprehensive training from your healthcare team is critical; studies show that administration mistakes are common and can make the treatment less effective at controlling insulin-like growth factor 1 (IGF-1) levels [6]. Examples of these mistakes include improperly mixing the powder with the liquid (shaking it instead of gently rolling it) or failing to rotate injection sites. Storage note: The unmixed vials must be stored in the refrigerator.

Oral Medications (Pills)

For patients looking to avoid injections entirely, there are oral alternatives available.

  • Cabergoline: This dopamine agonist is an oral pill usually taken just once or twice a week [7][8]. It is often prescribed for milder cases of acromegaly or as an “add-on” therapy alongside injections to help normalize IGF-1 levels [7][9]. It is safely stored at room temperature.
  • Oral Octreotide (Mycapssa): This is an FDA-approved pill form of octreotide taken twice daily [10][11]. Currently, it is available for patients who have already achieved biochemical control—meaning their hormone levels (like IGF-1) are already stabilized on injectable SRLs and they tolerate the medications well [10][12]. Because food significantly reduces the absorption of the medication in the gut, these capsules must be taken on a strictly empty stomach—at least one hour before a meal or two hours after [13][14]. Switching to oral capsules has been shown to eliminate injection-site pain or nodules and improve overall treatment satisfaction [15][16]. Storage note: Unopened bottles must be refrigerated, though opened bottles can be kept at room temperature for up to a month.

Common questions in this guide

Can I take acromegaly medication as a pill instead of an injection?
Yes, oral alternatives are available for some patients who want to avoid injections. Cabergoline is a pill typically taken once or twice a week, while oral octreotide is a twice-daily pill for those whose hormone levels are already stable on injections.
Do I need to go to a clinic for my acromegaly injections?
It depends on the specific medication your doctor prescribes. Deep intramuscular injections like octreotide LAR must be given by a healthcare professional in a clinic, but some subcutaneous medications like lanreotide or pegvisomant can be self-administered at home.
How often do I need to take acromegaly injections?
Long-acting injections like octreotide and lanreotide are usually given once every four weeks, though this interval can sometimes be extended if your hormones are stable. Other medications, such as pegvisomant, require a daily injection under the skin.
Can I store my acromegaly medications at room temperature?
Most injectable acromegaly medications, such as octreotide and pegvisomant, must be stored in the refrigerator. However, cabergoline pills can be kept at room temperature, and opened bottles of oral octreotide are also safe at room temperature for up to a month.
Why do I have to take oral octreotide on an empty stomach?
Food significantly reduces the absorption of oral octreotide in the gut. To ensure the medication works properly, the capsules must be taken strictly on an empty stomach—at least one hour before eating or two hours after a meal.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current hormone levels, am I a candidate for oral medications like cabergoline or octreotide capsules, or do I require an injectable option?
  2. 2.If I am prescribed an injectable medication, can it be self-administered at home by myself or my partner, or do I need to schedule monthly clinic visits?
  3. 3.What kind of injection-site reactions should I expect with this specific medication, and what can I do to minimize the soreness or nodules?
  4. 4.If my IGF-1 levels become very stable on my monthly injection, is there a possibility we could extend the time between doses to every 6 or 8 weeks?
  5. 5.If I struggle with self-administering a daily injection like Pegvisomant, what resources, home nursing, or training can the clinic provide?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Will My Face and Hands Go Back to Normal After Acromegaly?How Does Acromegaly Affect Fertility and Pregnancy?Does Acromegaly Cause Severe Headaches? Causes & ReliefDoes Acromegaly Cause Jaw Changes and Malocclusion?Does Acromegaly Cause Joint Pain? Is It Reversible?Does Acromegaly Cause Voice Changes & Vocal Thickening?How Is Transsphenoidal Surgery for Acromegaly Performed?Is Acromegalic Cardiomyopathy Reversible?Is Acromegaly Hereditary? Genetic Causes ExplainedAcromegaly and Anesthesia: What Are the Airway Risks?What Are the Second-Line Treatments for Acromegaly?What Are the Side Effects of Acromegaly Radiation?What does the Knosp grade mean on a pituitary MRI?GH vs IGF-1 in Acromegaly: What is the Difference?What Is the Life Expectancy for Acromegaly Patients?Why Do Acromegaly Patients Need Frequent Colonoscopies?Why is Gadolinium Contrast Used for Pituitary MRIs?Why Monitor IGF-1 Instead of Growth Hormone on PegvisomantWhy is an Oral Glucose Tolerance Test Used for Acromegaly?

References

References (16)
  1. 1

    Neuroendocrine tumours - Medical therapy: Biological.

    Rinke A, Krug S

    Best practice & research. Clinical endocrinology & metabolism 2016; (30(1)):79-91.

    PMID: 26971845
  2. 2

    Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).

    Ström T, Kozlovacki G, Myrenfors P, Almquist M

    Patient preference and adherence 2019; (13()):1799-1807 doi:10.2147/PPA.S213472.

    PMID: 31695341
  3. 3

    Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.

    Bronstein MD, Fleseriu M, Neggers S, et al.

    BMC endocrine disorders 2016; (16()):16 doi:10.1186/s12902-016-0096-8.

    PMID: 27039081
  4. 4

    Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.

    Gurel MH, Han Y, Stevens AL, et al.

    BMC pharmacology & toxicology 2017; (18(1)):22 doi:10.1186/s40360-017-0124-y.

    PMID: 28372573
  5. 5

    Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.

    Peral C, Cordido F, Gimeno-Ballester V, et al.

    Expert review of pharmacoeconomics & outcomes research 2020; (20(1)):105-114 doi:10.1080/14737167.2019.1610396.

    PMID: 31055976
  6. 6

    Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study.

    Cámara R, Venegas E, García-Arnés JA, et al.

    Pituitary 2019; (22(2)):137-145 doi:10.1007/s11102-019-00943-1.

    PMID: 30756345
  7. 7

    Real-world value of cabergoline in the treatment of acromegaly.

    Shimon I

    Best practice & research. Clinical endocrinology & metabolism 2024; (38(4)):101887 doi:10.1016/j.beem.2024.101887.

    PMID: 38443225
  8. 8

    Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center.

    Sahin S, Fidan MC, Korkmaz OP, et al.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2021; (129(9)):644-650 doi:10.1055/a-1274-1276.

    PMID: 33096579
  9. 9

    Cabergoline in acromegaly.

    Kuhn E, Chanson P

    Pituitary 2017; (20(1)):121-128 doi:10.1007/s11102-016-0782-6.

    PMID: 28025719
  10. 10

    Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly.

    Uygur MM, Villanova M, Frara S, Giustina A

    TouchREVIEWS in endocrinology 2024; (20(1)):37-42 doi:10.17925/EE.2024.20.1.9.

    PMID: 38812667
  11. 11

    Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly.

    Yuen KCJ, Samson SL

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(6)):637-645 doi:10.1016/j.eprac.2022.04.009.

    PMID: 35452815
  12. 12

    Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.

    Fleseriu M, Dreval A, Bondar I, et al.

    The lancet. Diabetes & endocrinology 2022; (10(2)):102-111 doi:10.1016/S2213-8587(21)00296-5.

    PMID: 34953531
  13. 13

    Update on the use of oral octreotide therapy for acromegaly.

    Schilbach K, Schopohl J

    Expert review of endocrinology & metabolism 2016; (11(4)):349-355 doi:10.1080/17446651.2016.1199954.

    PMID: 30058923
  14. 14

    A QbD-informed study of permeation enhancer-octreotide nanoscale interactions influencing performance in pullulan buccal films.

    Malhotra S, Karki S, Linford H, et al.

    International journal of pharmaceutics 2026; (694()):126730 doi:10.1016/j.ijpharm.2026.126730.

    PMID: 41771310
  15. 15

    MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly.

    Fleseriu M, Molitch M, Dreval A, et al.

    The Journal of clinical endocrinology and metabolism 2023; (108(12)):3214-3222 doi:10.1210/clinem/dgad365.

    PMID: 37319438
  16. 16

    Oral Octreotide Capsules and Paltusotine in Management of Acromegaly.

    McLaren DS, Seejore K, Lynch J, Murray RD

    TouchREVIEWS in endocrinology 2024; (20(1)):32-36 doi:10.17925/EE.2023.20.1.3.

    PMID: 38812672

This page provides educational information about acromegaly medication administration and storage. Always consult your endocrinologist regarding your specific treatment plan, medication choices, and proper injection techniques.

Get notified when new evidence is published on Acromegaly.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.